Trial Profile
A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of NMT-cP12 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Sep 2020
Price :
$35
*
At a glance
- Drugs NMT-cP12 (Primary)
- Indications Burns
- Focus Adverse reactions; Pharmacokinetics
- Sponsors NeoMatrix Therapeutics
- 24 Sep 2020 Topline results presented in a NeoMatrix Therapeutics media release.
- 07 Nov 2017 New trial record
- 31 Oct 2017 According to a NeoMatrix Therapeutics media release, the Investigational New Drug Application (IND) filed by the company for NMT-cP12 has gone into effect per the U.S. Food and Drug Administration (FDA) and the company plans to initiate this trial as soon as possible.